Arcturus Therapeutics is advancing mRNA therapies with ARCT-810 targeting OTC deficiency, showing positive phase 2 interim results that normalize glutamine and ammonia levels. The drug has FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations, highlighting its potential. A virtual presentation on September 23 will provide more data, which could impact the stock, though small trial sizes mean results are preliminary. The company holds $191.5 million in cash, supporting operations through 2028 amid sector risks and competition.
Arcturus Therapeutics' OTC deficiency program is progressing with promising phase 2 results. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 21, 2026 22:32 WIB: out of 95 priced US health-sector stocks, 52 rose and 41 fell. Notable movers include MRNA (Moderna, Inc.) at USD 168.75 with a +9.55% change and a typical hold time of 60 days, HRTX (Heron Therapeutics Inc) at USD 0.28 down -8.62% with a 35-day hold, and NVO (Novo Nordisk A/S) at USD 39.76 down -8.05% with a 114-day hold time.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
World Liberty Financial has launched a governance vote proposing a new rewards program for WLFI token holders. To earn rewards, holders must lock their tokens for 180 days and actively vote on governance proposals at least once every 90 days, with de...
Bitcoin's price approached $86,000, its highest level in eight months, marking a 6% increase in 24 hours and over 30% since August 19. Despite this rise, US spot demand remains weak as indicated by the slightly negative Coinbase premium, suggesting l...
Kraken's parent company, Payward, announced plans to offer perpetual futures on the Hyperliquid blockchain via the regulated Bitnomial exchange in the U.S., driving the HYPE token price close to $100. However, this plan is still a proposal awaiting r...
